Burning Rock Biotech
BNR
34 hedge funds and large institutions have $60.8M invested in Burning Rock Biotech in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 16 reducing their positions, and 10 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
23% more capital invested
Capital invested by funds: $49.5M → $60.8M (+$11.3M)
0.04% less ownership
Funds ownership: 2.49% → 2.45% (-0.04%)
17% less funds holding
Funds holding: 41 → 34 (-7)
50% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 16
70% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$1.88M |
| 2 |
Millennium Management
New York
|
+$1.59M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
+$247K |
| 4 |
PCM
Prelude Capital Management
New York
|
+$98.5K |
| 5 |
RWMG
Redwood Wealth Management Group
Medford,
New Jersey
|
+$40.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
-$1.53M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$734K |
| 3 |
Morgan Stanley
New York
|
-$415K |
| 4 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$328K |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$237K |
BNR Hedge Fund Activity: Q1 2023 in Review
34 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Burning Rock Biotech (BNR) for Q1 2023, worth a combined $60.8M — up 23% from $49.5M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of BNR and 3 opened new positions — a net loss of 7 holders — while 16 trimmed existing stakes and 8 added.
The largest buyer was Kynam Capital Management, adding an estimated $1.88M. The largest seller was Barclays, cutting an estimated $1.53M.
- 34 institutional investors held Burning Rock Biotech (BNR) as of Q1 2023, down from 41 in Q4 2022.
- Funds reported $60.8M of Burning Rock Biotech stock for Q1 2023, up 23% quarter-over-quarter.
- 3 funds opened new Burning Rock Biotech positions in Q1 2023 and 10 closed out, a net change of -7 holders.
- The largest Burning Rock Biotech buyer in Q1 2023 was Kynam Capital Management, an estimated $1.88M added.
- The largest Burning Rock Biotech seller in Q1 2023 was Barclays, an estimated $1.53M sold.
Based on aggregated 13F filings for Q1 2023.